Faculty Profile: Teri Pearlstein, MD

Teri Pearlstein, MD
Associate Professor of Psychiatry & Human Behavior and Associate Professor of Medicine
Psychiatry & Human Behavior
Work: +1 401-793-7020
My major research interest has been the assessment and treatment of women with premenstrual dysphoric disorder (PMDD). Studies have included impact of PMDD on function and efficacy of antidepressant medications and oral contraceptives in PMDD. I have also conducted treatment trials in dysthymia, post-traumatic stress disorder, binge eating disorder, and postpartum depression.

Institutions

Wih

Research Description

My major research interest has been the assessment and treatment of women with premenstrual dysphoric disorder (PMDD). Seminal studies have included the impact of PMDD on functioning and the efficacy of antidepressant medications and oral contraceptives in PMDD. These studies have included the first placebo-controlled SSRI (fluoxetine) trial in PMDD in the United States (1991), the largest and longest-term naturalistic follow-up study of women with PMDD (1994), a placebo-controlled comparison of fluoxetine and buproprion in PMDD that exhibited the lack of efficacy of nonserotonergic antidepressants in PMDD (1997), the establishment of the efficacy of an oral contraceptive for PMDD (2005), and a study reporting the benefit of sertraline on psychosocial functioning in a large sample of women with PMDD (2000), which remains the largest comprehensive study of social functioning and quality of life in PMDD.

I have also conducted treatment trials in dysthymia, post-traumatic stress disorder (PTSD), binge eating disorder, and postpartum depression. I have been the second author on two large placebo-controlled sertraline studies in PTSD published in the American Journal of Psychiatry (2001) and the Journal of the American Medical Association (JAMA, 2000). My current research interests include the evaluation of treatment efficacy and adverse effects, and factors governing patient treatment choice, in perinatal depression.

Grants and Awards

None

Affiliations

MEMBERSHIP IN SOCIETIES

1983 - 1986 American Medical Association
1986 - 1990 Psychiatric Physicians of Pennsylvania
1987 - 1990 Society of Menstrual Cycle Research
1987 - 1990 American Society for Psychosomatic Obstetrics and Gynecology
1996 - 1998 Secretary, Rhode Island Medical Women's Association
1997 - 2002 American Medical Women's Association
1997 - 2004 North American Menopause Society
2002 - 2004 American Society of Clinical Psychopharmacology
2003 - 2005 Member-at-Large, Executive Committee, North American Society for Psychosocial Obstetrics and Gynecology
2009 - 2011 President-Elect, North American Society for Psychosocial Obstetrics and Gynecology
1984 - American Psychiatric Association
1990 - Rhode Island Psychiatric Society
1994 - Rhode Island Medical Women's Association
1996 - North American Society for Psychosocial Obstetrics and Gynecology
1999 - Fellow, American Psychiatric Association
2002 - International Association for Women's Mental Health
2002 - Treasurer, Executive Committee, International Association for Women's Mental Health
2003 - Distinguished Fellow, American Psychiatric Association
2011 - President, North American Society for Psychosocial Obstetrics and Gynecology

Funded Research

GRANTS

1. Comparison of Fluoxetine and Placebo in the Treatment of Premenstrual Syndrome, Co-P.I. (Andrea Stone, PI), 1988-90, ($20,000), Eli Lilly.

2. Double-Blind Parallel Comparison of Sertraline, Imipramine and Placebo in Outpatients with Dysthymia, Protocol #R-0211, P.I., 1991-93, ($150,000), Pfizer.

3. Double-Blind Follow-up Study of Sertraline, Imipramine and Placebo in Outpatients with Dysthymia, Protocol #R-0222, P.I., 1992-94, ($150,000), Pfizer.

4. Double-Blind Parallel Comparison of Sertraline and Placebo in Patients with Premenstrual Dysphoric Disorder, Protocol #R-0256, P.I., 1992-94, ($149,000), Pfizer.

5. Comparison of Fluoxetine, Bupropion and Placebo in Late Luteal Phase Dysphoric Disorder, Co-P.I. (Andrea Stone, PI), 1992-95, ($31,000), Eli Lilly.

6. Double-Blind Comparison of Sertraline and Placebo in Outpatients with Post-Traumatic Stress Disorder, Protocol #93CE21-0640, P.I., 1994-96, ($50,000), Pfizer.

7. A Double-Blind Flexible Dose Study Comparing Sertraline and Placebo in Outpatients with Post-Traumatic Stress Disorder, Protocol #95CE21-0671, P.I., 1996-97, ($40,000), Pfizer.

8. A Placebo-Controlled, Double-Blind, Flexible Dose Study of Sertraline in the Treatment of Post-Traumatic Stress Disorder, Protocol #96CE21-0682, P.I., 1997, ($10,000), Pfizer.

9. A 24-Week Open-Label Extension Study of Sertraline in Outpatients with Post-Traumatic Stress Disorder, Protocol #95CE21-0672, P.I., 1996-98, ($50,000), Pfizer.

10. A Double-Blind Continuation Study Comparing Sertraline and Placebo in Outpatients with Post-Traumatic Stress Disorder, Protocol #96CE21-0703, P.I., 1997-98, ($15,000), Pfizer.

11. Double Blind Parallel Comparison of Luteal Phase Dosing with Sertraline and Placebo in Patients with Premenstrual Dysphoric Disorder, Protocol #R-0493, P.I., 1996-99, ($120,000), Pfizer.

12. A Double-Blind Comparison of Fixed Dose Sertraline and Placebo in the Treatment of Premenstrual Syndrome, Protocol #96CE21-0680, P.I., 1997-99, ($90,000), Pfizer.

13. Treatment of Binge Eating Disorder with Fluvoxamine: A Double-Blind, Placebo-Controlled Trial, P.I., 1997-98, ($45,000), Solvay.

14. Combined Dialectical Behavior Therapy and Fluoxetine Treatment of Women with Borderline Personality Disorder, P.I., 1997-98, Executive Council On Research (ECOR) Grant, ($15,800), Department of Psychiatry and Human Behavior, Brown University School of Medicine.

15. A Multicenter, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy of a Monophasic Oral Contraceptive Preparation Containing Drosperinone 3 mg and Ethinyl Estradiol 30 µg in the Treatment of Premenstrual Syndrome, Protocol #97036, P.I., 1997-99, ($20,000), Berlex.

16. Combined Dialectical Behavior Therapy and Fluoxetine Pharmacotherapy in Patients with Borderline Personality Disorder, P.I., 1997-99, ($45,000), Eli Lilly.

17. Fluoxetine versus Placebo in Posttraumatic Stress Disorder, Protocol #B1Y-MC-HCJL, P.I., 1999, ($10,000), Eli Lilly.

18. Validation of the Calendar of Premenstrual Experiences (COPE), Protocol #99014, P.I., 1999, ($25,000), Berlex.

19. Intermittent Dosing of Fluoxetine in the Treatment of Premenstrual Dysphoric Disorder: Luteal Phase Daily Dosing versus Placebo, Protocol #B1Y-MC-HCJN, P.I., 1998-2000, ($75,000), Eli Lilly.

20. Duloxetine versus Placebo in the Treatment of Major Depression, Protocol #F1J-MC-HMAQ, P.I., 1999-2000, ($20,000), Eli Lilly.

21. A Phase 2 Study of the Use of PH80 for Management of the Symptoms of Clinically Significant Premenstrual Syndrome (PMS), Protocol #PH80 CL015, P.I., 2000-01, ($12,000), Pherin Pharmaceuticals.

22. A Multicenter, Double-Blinded, Randomized, Placebo-Controlled, Parallel Group Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge Eating Disorder, Protocol #SB237, P.I., 2000-01, ($75,000), Knoll Pharmaceuticals.

23. A Double-Blind, Placebo-Controlled, 3-Arm Fixed Dose Study of Paroxetine CR Continuous Treatment (12.5 mg and 25 mg/day) for Premenstrual Dysphoric Disorder, Protocol #677, P.I., 2000-02, ($60,000), SmithKline Beecham.

24. A 3-Month, Double-Blind, Placebo-Controlled, Fixed Dose, Extension Study of Paroxetine CR (12.5 mg and 25 mg/day) Continuous Treatment for PMDD Patients completing Studies 29060/677, 688 or 689, Protocol #711, P.I., 2000-02, ($15,000), SmithKline Beecham.

25. A Double-Blind, Randomized, Placebo-Controlled, 3-Month Clinical Trial of Venlafaxine ER and Sertraline in the Treatment of Posttraumatic Stress Disorder, Protocol #0600B-100735, P.I., 2001-02, ($64,000), Wyeth-Ayerst.

26. A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of a Monophasic Oral Contraceptive Preparation Containing Drospirenone 3 mg Ethinyl Estradiol 20 µg (as Beta-Cyclodextrin Clathrate) in the Treatment of Premenstrual Dysphoric Disorder (PMDD), Protocol #305141, P.I., 2002, ($10,000), Berlex.

27. A Multicenter, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy of a Monophasic Oral Contraceptive Preparation Containing Drospirenone 3 mg Ethinyl Estradiol 20 µg (as Beta-Cyclodextrin Clathrate) in the Treatment of Premenstrual Dysphoric Disorder, Protocol #304049, P.I., 2000-03, ($45,000), Berlex.

28. A Comparison of Calcium and Fluoxetine as PMDD Treatments, Co-Principal Investigator (PI: KA Yonkers), 2000-05, ($84,000), Ethel F. Donaghue Women's Health Investigator Program, Yale University School of Medicine.

29. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Moderate to Severe Binge-Eating Disorder Associated with Obesity, Protocol #CAPSS-220, P.I., 2003-05, ($60,000), Ortho-McNeil.

30. Treating PMS/PMDD: Research versus Clinical Reality. Co-Principal Investigator (PI: KA Yonkers), 9/30/01-8/31/05, Annual Direct Cost: $40,000 (Subcontract). National Institute of Mental Health (NIMH) R21 MH62379,

31. Depression Prevention for Poor Pregnant Women. Co-Investigator (PI: C Zlotnick), 6/1/06-4/30/11. NIMH R01 MH71766,